Core Evidence

Aims and Scope

Editor-in-Chief: Professor Garry Walsh

Core Evidence evaluates the evidence underlying the potential place in therapy of drugs throughout their development lifecycle from preclinical to postlaunch. The focus of each review is to evaluate the case for a new drug or class in outcome terms in specific indications and patient groups. The journal encourages the submission of unsolicited review articles.

Core Evidence will no longer consider meta-analyses for publication.